Tvardi Therapeutics, Inc.(TVRD)Earnings, Financials & Key Ratios
TVRD•NASDAQ
$1.87
Price updated Jun 27, 2026
AboutTvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).Show more
- Revenue$0-100.0%
- EBITDA-$27M+52.1%
- Net Income-$18M+74.3%
- EPS (Diluted)-3.26+93.0%
- ROE-222.76%
TVRD Price & Volume
Tvardi Therapeutics, Inc. (TVRD) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2025Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
Key Thesis Takeaways
- Tvardi Therapeutics remains a high-risk, pre-commercial biotechnology entity heavily reliant on external capital to sustain its STAT3-focused clinical pipeline.
- While the company has successfully reduced its quarterly R&D burn from $28.4M in 2023Q4 to $5.5M in 2025Q4, the lack of consistent revenue generation poses a significant threat to long-term solvency.
- Investors should monitor the company's ability to secure non-dilutive funding or strategic partnerships, as the current cash position of $20.7M provides limited runway for ongoing Phase 2 trials.
Verdict Logic
the company's precarious liquidity profile, evidenced by a cash balance of only $20.7M against a history of substantial quarterly operating losses, suggests a high probability of future dilutive financing.
TVRD Growth Metrics
Tvardi Therapeutics, Inc. (TVRD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM20.33%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM75.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM90.26%
Return on Capital
10 Years-123.24%
5 Years-148.31%
3 Years-213.28%
Last Year-87.86%
TVRD Recent Earnings
Tvardi Therapeutics, Inc. (TVRD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/5 qtrs (20%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.73-12.3%
$0.65
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.78-41.8%
$0.55
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.59+28.9%
$0.83
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.00-96.1%
$0.51
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.73vs $0.65-12.3% | — |
| Q2 2026 | Mar 31, 2026 | $0.78vs $0.55-41.8% | — |
| Q4 2025 | Nov 13, 2025 | $0.59vs $0.83+28.9% | — |
| Q3 2025 | Aug 14, 2025 | $1.00vs $0.51-96.1% | — |
Based on last 5 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Tvardi Therapeutics, Inc. (TVRD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.87 | $17.54M | -0.57 | -100% | — | -222.76% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $17.23 | $2.22B | 8.32 | 20.38% | 99.97% | 64.48% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — |
Compare TVRD vs Peers
Tvardi Therapeutics, Inc. (TVRD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when TVRD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TVRD Frequently Asked Questions
Tvardi Therapeutics, Inc. (TVRD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Tvardi Therapeutics, Inc.'s revenue?
Tvardi Therapeutics, Inc. (TVRD) reported $2.6M in revenue for fiscal year 2025. This represents a 98% decrease from $135.1M in 2020.
How fast is Tvardi Therapeutics, Inc. growing?
Tvardi Therapeutics, Inc. (TVRD) saw revenue decline by 100.0% over the past year.
Is TVRD profitable?
Tvardi Therapeutics, Inc. (TVRD) reported a net loss of $13.5M for fiscal year 2025.
Dividend & Returns
What is TVRD's return on equity?
Tvardi Therapeutics, Inc. (TVRD) has a return on equity (ROE) of -222.8%. Negative ROE indicates the company is unprofitable.
What is Tvardi Therapeutics, Inc.'s free cash flow?
Tvardi Therapeutics, Inc. (TVRD) had negative free cash flow of $23.5M in fiscal year 2025, likely due to heavy capital investments.